

FORM D
Notice of Exempt Offering of Securities

UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C.

OMB APPROVAL
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hours per response: 4.0

1. Issuer's Identity

CIK (Filer ID Number)	Previous Name(s) <input type="checkbox"/> None	Entity Type
<input type="text" value="0001228627"/>	<input type="text" value="REXAHN
PHARMACEUTICALS,
INC."/>	<input checked="" type="radio"/> Corporation
Name of Issuer		<input type="radio"/> Limited Partnership
<input type="text" value="Ocuphire Pharma, Inc."/>	<input type="text" value="CORPORATE ROAD
SHOW DOT COM INC"/>	<input type="radio"/> Limited Liability Company
Jurisdiction of Incorporation/Organization		<input type="radio"/> General Partnership
<input type="text" value="DELAWARE"/>		<input type="radio"/> Business Trust
Year of Incorporation/Organization		<input type="radio"/> Other
<input checked="" type="radio"/> Over Five Years Ago		
<input type="radio"/> Within Last Five Years (Specify Year)	<input type="text"/>	
<input type="radio"/> Yet to Be Formed		

2. Principal Place of Business and Contact Information

Name of Issuer			
<input type="text" value="Ocuphire Pharma, Inc."/>			
Street Address 1		Street Address 2	
<input type="text" value="37000 GRAND RIVER AVE."/>		<input type="text" value="SUITE 120"/>	
City	State/Province/Country	ZIP/Postal Code	Phone No. of Issuer
<input type="text" value="FARMINGTON HILLS"/>	<input type="text" value="MICHIGAN"/>	<input type="text" value="48335"/>	<input type="text" value="248-681-9815"/>

3. Related Persons

Last Name	First Name	Middle Name	
<input type="text" value="Sooch"/>	<input type="text" value="Mina"/>		
Street Address 1		Street Address 2	
<input type="text" value="c/o Ocuphire Pharma, Inc."/>		<input type="text" value="37000 Grand River Ave., Suite 120"/>	
City	State/Province/Country	ZIP/Postal Code	
<input type="text" value="Farmington Hills"/>	<input type="text" value="MICHIGAN"/>	<input type="text" value="48335"/>	
Relationship:	<input checked="" type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director	<input type="checkbox"/> Promoter
Clarification of Response (if Necessary)			
<input type="text"/>			

Last Name	First Name	Middle Name	
<input type="text" value="Meyer"/>	<input type="text" value="Alan"/>	<input type="text" value="R."/>	
Street Address 1		Street Address 2	
<input type="text" value="c/o Ocuphire Pharma, Inc."/>		<input type="text" value="37000 Grand River Ave, Suite 120"/>	
City	State/Province/Country	ZIP/Postal Code	
<input type="text" value="Farmington Hills"/>	<input type="text" value="MICHIGAN"/>	<input type="text" value="48335"/>	
Relationship:	<input type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director	<input type="checkbox"/> Promoter

Clarification of Response (if Necessary)

Last Name

First Name

Middle Name

Ainsworth

Sean

Street Address 1

Street Address 2

c/o Ocuphire Pharma, Inc.

37000 Grand River Ave, Suite 120

City

State/Province/Country

ZIP/Postal Code

Farmington Hills

MICHIGAN

48335

Relationship:

☐ Executive Officer

☒ Director

☐ Promoter

Clarification of Response (if Necessary)

Last Name

First Name

Middle Name

Manuso

James

S.

Street Address 1

Street Address 2

c/o Ocuphire Pharma, Inc.

37000 Grand River Ave, Suite 120

City

State/Province/Country

ZIP/Postal Code

Farmington Hills

MICHIGAN

48335

Relationship:

☐ Executive Officer

☒ Director

☐ Promoter

Clarification of Response (if Necessary)

Last Name

First Name

Middle Name

Gallagher

Cam

Street Address 1

Street Address 2

c/o Ocuphire Pharma, Inc.

37000 Grand River Ave, Suite 120

City

State/Province/Country

ZIP/Postal Code

Farmington Hills

MICHIGAN

48335

Relationship:

☐ Executive Officer

☒ Director

☐ Promoter

Clarification of Response (if Necessary)

Last Name

First Name

Middle Name

Benton

Susan

K.

Street Address 1

Street Address 2

c/o Ocuphire Pharma, Inc.

37000 Grand River Ave, Suite 120

City

State/Province/Country

ZIP/Postal Code

Farmington Hills

MICHIGAN

48335

Relationship:

☐ Executive Officer

☒ Director

☐ Promoter

Clarification of Response (if Necessary)

Last Name	First Name	Middle Name
<input type="text" value="Rodgers"/>	<input type="text" value="Richard"/>	<input type="text" value="J."/>
Street Address 1	Street Address 2	
<input type="text" value="c/o Ocuphire Pharma, Inc."/>	<input type="text" value="37000 Grand River Ave, Suite 120"/>	
City	State/Province/Country	ZIP/Postal Code
<input type="text" value="Farmington Hills"/>	<input type="text" value="MICHIGAN"/>	<input type="text" value="48335"/>
Relationship:	<input type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director
<input type="checkbox"/> Promoter		
Clarification of Response (if Necessary)		
<input type="text"/>		

Last Name	First Name	Middle Name
<input type="text" value="Hoffmann"/>	<input type="text" value="Bernhard"/>	
Street Address 1	Street Address 2	
<input type="text" value="c/o Ocuphire Pharma, Inc."/>	<input type="text" value="37000 Grand River Ave, Suite 120"/>	
City	State/Province/Country	ZIP/Postal Code
<input type="text" value="Farmington Hills"/>	<input type="text" value="MICHIGAN"/>	<input type="text" value="48335"/>
Relationship:	<input checked="" type="checkbox"/> Executive Officer	<input type="checkbox"/> Director
<input type="checkbox"/> Promoter		
Clarification of Response (if Necessary)		
<input type="text"/>		

Last Name	First Name	Middle Name
<input type="text" value="Zaremba Rabourn"/>	<input type="text" value="Amy"/>	
Street Address 1	Street Address 2	
<input type="text" value="c/o Ocuphire Pharma, Inc."/>	<input type="text" value="37000 Grand River Ave, Suite 120"/>	
City	State/Province/Country	ZIP/Postal Code
<input type="text" value="Farmington Hills"/>	<input type="text" value="MICHIGAN"/>	<input type="text" value="48335"/>
Relationship:	<input checked="" type="checkbox"/> Executive Officer	<input type="checkbox"/> Director
<input type="checkbox"/> Promoter		
Clarification of Response (if Necessary)		
<input type="text"/>		

4. Industry Group

☐ Agriculture

Banking & Financial Services

☐ Commercial Banking
 ☐ Insurance
 ☐ Investing
 ☐ Investment Banking
 ☐ Pooled Investment Fund
 ☐ Other Banking & Financial Services

☐ Business Services

Energy

☐ Coal Mining
 ☐ Electric Utilities
 ☐ Energy Conservation
 ☐ Environmental Services
 ☐ Oil & Gas
 ☐ Other Energy

Health Care

☒ Biotechnology
 ☐ Health Insurance
 ☐ Hospitals & Physicians
 ☐ Pharmaceuticals
 ☐ Other Health Care

☐ Manufacturing

Real Estate

☐ Commercial
 ☐ Construction
 ☐ REITS & Finance
 ☐ Residential
 ☐ Other Real Estate

☐ Retailing

Restaurants

Technology

☐ Computers
 ☐ Telecommunications
 ☐ Other Technology

Travel

☐ Airlines & Airports
 ☐ Lodging & Conventions
 ☐ Tourism & Travel Services
 ☐ Other Travel

☐ Other

5. Issuer Size

Revenue Range

☐ No Revenues
 ☐ \$1 - \$1,000,000
 ☐ \$1,000,001 - \$5,000,000
 ☐ \$5,000,001 - \$25,000,000
 ☐ \$25,000,001 - \$100,000,000
 ☐ Over \$100,000,000
 ☒ Decline to Disclose
 ☐ Not Applicable

Aggregate Net Asset Value Range

☐ No Aggregate Net Asset Value
 ☐ \$1 - \$5,000,000
 ☐ \$5,000,001 - \$25,000,000
 ☐ \$25,000,001 - \$50,000,000
 ☐ \$50,000,001 - \$100,000,000
 ☐ Over \$100,000,000
 ☐ Decline to Disclose
 ☐ Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

<input type="checkbox"/>	Rule 504(b)(1) (not (i), (ii) or (iii))	<input type="checkbox"/>	Rule 505	
<input type="checkbox"/>	Rule 504 (b)(1)(i)	<input checked="" type="checkbox"/>	Rule 506(b)	
<input type="checkbox"/>	Rule 504 (b)(1)(ii)	<input type="checkbox"/>	Rule 506(c)	
<input type="checkbox"/>	Rule 504 (b)(1)(iii)	<input type="checkbox"/>	Securities Act Section 4(a)(5)	
<input type="checkbox"/>		<input type="checkbox"/>	Investment Company Act Section 3(c)	

7. Type of Filing

☒ New Notice
 Date of First Sale

2020-11-05

☐ First Sale Yet to Occur

☐ Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?

☐ Yes
 ☒ No

9. Type(s) of Securities Offered (select all that apply)

☐ Pooled Investment Fund Interests
 ☒ Equity
 ☐ Tenant-in-Common Securities
 ☐ Debt

☐ Mineral Property Securities ☒ Option, Warrant or Other Right to Acquire Another Security

☒ Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security ☐ Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? ☒ Yes ☐ No

Clarification of Response (if Necessary)

In connection with the merger between Ocuphire and Rexahn Pharmaceuticals Inc., Ocuphire entered into a securities purchase agreement providing for the issuance of Ocuphire common stock and warrants to purchase Rexahn common stock to accredited investors.

11. Minimum Investment

Minimum investment accepted from any outside investor \$ USD

12. Sales Compensation

Recipient Recipient CRD Number ☐ None

(Associated) Broker or Dealer ☒ None (Associated) Broker or Dealer CRD Number ☒ None

Street Address 1 Street Address 2

City State/Province/Country ZIP/Postal Code

State(s) of Solicitation ☐ All States ☐ Foreign/Non-US

Recipient Recipient CRD Number ☐ None

(Associated) Broker or Dealer ☒ None (Associated) Broker or Dealer CRD Number ☒ None

Street Address 1 Street Address 2

City State/Province/Country ZIP/Postal Code

State(s) of Solicitation ☐ All States ☐ Foreign/Non-US

ILLINOIS
MARYLAND
ARIZONA
NEW YORK
MICHIGAN
CALIFORNIA

13. Offering and Sales Amounts

Total Offering Amount \$ USD ☐ Indefinite

Total Amount Sold \$ USD

Total Remaining to be Sold \$ USD ☐ Indefinite

Clarification of Response (if Necessary)

14. Investors

☐

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$ USD ☒ Estimate

Finders' Fees \$ USD ☐ Estimate

Clarification of Response (if Necessary)

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$ USD ☐ Estimate

Clarification of Response (if Necessary)

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Ocuphire Pharma, Inc.	/s/ Bernhard Hoffmann	Bernhard Hoffmann	VP - Corporate Development and Finance	2020-11-20